Amneal Pharmaceuticals, Inc. Press Releases https://investors.amneal.com/generated by Q4Sat, 15 Aug 2026 16:13:36 -0400Copyright Q4 Inc. All rights reserved.Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leaderb6e3b602-2796-48d2-a39e-745b312a2d60https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Completes-Acquisition-of-Kashiv-BioSciences-Creating-a-Global-Biosimilar-Leader/default.aspxMon, 10 Aug 2026 08:00:00 -0400Amneal Reports Second Quarter 2026 Financial Results72066fa7-9dd5-43a4-94c4-d3e80132f342https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Reports-Second-Quarter-2026-Financial-Results/default.aspxThu, 30 Jul 2026 06:00:00 -0400Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentationsfcaba9f6-e17d-46ab-be5a-cb1e3152df93https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Expands-Iohexol-Injection-Portfolio-with-U-S--FDA-Approval-of-Additional-Strengths-and-Presentations/default.aspxFri, 17 Jul 2026 08:00:00 -0400Amneal to Report Second Quarter 2026 Results on July 30, 202638b89989-9732-4b62-82dc-7a996dc0da18https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Report-Second-Quarter-2026-Results-on-July-30-2026/default.aspxThu, 09 Jul 2026 16:05:00 -0400Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjectorcf1c72d4-fd8e-45a0-9f49-fda399156561https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-and-Adalvo-Announce-FDA-Acceptance-for-Review-of-Two-U-S--ANDAs-for-Generic-Tirzepatide-Autoinjector-2026-_ei9_NKxPV/default.aspxWed, 08 Jul 2026 16:30:00 -0400Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program 9cef266f-02e0-4ec5-971f-bc63c1793ebdhttps://investors.amneal.com/news/press-releases/press-release-details/2026/Amneals-New-U-S--Sterile-Manufacturing-Facility-Selected-for-FDA-PreCheck-Pilot-Program--2026-Si4bsWWx9f/default.aspxWed, 01 Jul 2026 08:30:00 -0400Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuationsabe86d38-d2d9-49a2-a38b-7b2250590134https://investors.amneal.com/news/press-releases/press-release-details/2026/Zambon-and-Amneal-Announce-Positive-CHMP-Opinion-for-Hopledo-IPX203-for-Adults-with-Parkinsons-Disease-and-Moderate-to-Severe-Motor-Fluctuations/default.aspxMon, 29 Jun 2026 03:00:00 -0400Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Diseasec2bedb01-26b7-47a7-8273-524681a6a026https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-Full-Study-Population-Interim-Phase-4-ELEVATE-PD-Results-Reinforcing-Previously-Reported-Benefits-of-CREXONT-in-Parkinsons-Disease/default.aspxFri, 05 Jun 2026 08:00:00 -0400Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution65ad83a8-eed6-4d17-a029-e0d876d8b128https://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-Announces-U-S--FDA-Approval-of-Romidepsin-Injection-Solution/default.aspxThu, 04 Jun 2026 08:00:00 -0400Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026e0cfbcd8-b65f-45d9-8fd6-9ac6beb7884fhttps://investors.amneal.com/news/press-releases/press-release-details/2026/Amneal-to-Participate-in-Goldman-Sachs-47th-Annual-Global-Healthcare-Conference-2026/default.aspxMon, 01 Jun 2026 08:00:00 -0400